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Risk Prediction for Common Diseases
Paula W Yoon*
My topic for discussion today is whether the promising field of
genomics is going to allow us to more accurately predict who in
the population is at future risk for common chronic diseases.
Before attempting to answer this question, I will provide some
general background and will then give some specific examples in
the area of heart disease, diabetes, and obesity.
I work in the Office of Genomics and Disease Prevention at the
Centers for Disease Control ("CDC") and, like most of CDC, our
focus is on disease prevention. Our office has a crosscutting role,
working with all the programs at CDC to help them integrate
genomics into what they do, whether it is research, policy, or
practice.
The year 2003 was certainly the year of the human genome.
We celebrated the completion of the human genome project and
the fiftieth anniversary of Watson and Crick's discovery of the
double helix structure of DNA. 1 One headline claimed, "DNA has
changed the world: But now what?" That is the big question.
As scientists, we are pretty good at collecting DNA. We can
get DNA from all kinds of body fluids and parts; it is amazing
where we can find DNA.2 Our technology for analyzing DNA,
which now includes whole genome scans and chips, is also
improving immensely, rapidly becoming faster and cheaper. 3 But
what does this mean for the health of individuals, families, and
communities?
The work that the scientific community is doing can be thought
of on a continuum, a translation continuum from gene discovery to
tools and processes that can be used to prevent and treat disease.
Along that continuum, there are various research methods that are
used to study genomics. First, there are family studies or linkage
This article is not copyright protected under 17 U.S.C. § 105 (2005).
ScD, MPH, Epidemiologist, Office of Genomics and Disease
Prevention, Centers for Disease Control and Prevention (CDC). This work is
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1. Horace F. Judson, The Greatest Surprise for Everyone---Notes on the
50th Anniversary of the Double Helix, 348 New Eng. J. Med. 1712, 1712-14
(2003).
2. Lin Zhang et al., Whole Genome Amplification From a Single Cell:
Implicationsfor Genetic Analysis, 89 Proc. Natl. Acad. Sci. USA 5847, 584751(1992).
3. Alan E. Guttmacher & Francis S. Collins, Genomic Medicine--A
Primer,347 New Eng. J. Med. 1512, 1512-20 (2002).
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studies, which look for genetic differences within small groups.
Next, there are population studies of different kinds--case-control
studies, cohorts, and so forth. When established associations lead
to new genetic tests or tools, there are clinical trials. Finally, after
studying a test or tool under controlled circumstances, we need to
evaluate its validity and utility in real circumstances. This last
step---which should occur before it is introduced for widespread
clinical or public health application-is often skipped or glossed
over. I am going to come back to this validation gap at the end of
my talk. Certainly, the use of emerging technology like whole
genome scans and haplotype mapping make the field of genomic
research very exciting. The promise is there but we have a long
way to go from gene discovery to treatment and prevention of
disease.
When genomic applications, like genetic tests, are carried
successfully through the research continuum what are their
potential uses for treating and preventing disease? There are
basically four areas of potential application. First is the possibility
of guiding drug therapy. Pharmacogenomics, or individualized
medication based on genetically determined variation in effects, is
probably one of the most promising areas in the field of genomics
today.
There is individual variation in the enzymes that
metabolize, absorb, and transport pharmaceuticals. There has also
been some success in identifying genes that cause some individuals
to have extremely positive or extremely negative effects from
drugs. Another related example is the use of DNA probes to5
identify pathogens. For example, in the diagnosis of meningitis,
DNA probes can be used to determine fairly rapidly whether the
illness is due to bacteria or a virus and, specifically, which
pathogen. This allows for quicker application of the most effective
therapy.
A second way in which genomics can be used to prevent
disease is by modifying the environment. If we can identify
individuals who are more susceptible to disease because of their
genetic make-up, it may be possible to reduce their risk through
individual behavior changes, such as diet, exercise, or smoking
cessation. Environmental modification can also occur through
community interventions, such as spraying for mosquitoes or
4. Francis S. Collins et al., A Visionfor the Futureof Genomics Research:
A Blueprintfor the Genomic Era, 22 Nature 835, 839 (2003).
5. A. Backman et al., Evaluation of an Extended DiagnosticPCR Assay
for Detectionand Verification of the Common Causes of BacterialMeningitis in
CSF and OtherBiologicalSamples, 13 Molecular and Cellular Probes 49, 49-60
(1999).
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having more sidewalks in communities so people can walk to
school and work. Workplace interventions are another possibility.
For example, if we know that within a particular workplace certain
people are more susceptible to substances like chemicals and
pesticides, exposures levels can be lowered for the safety of
everyone.
Gene therapy is another potential option for treating disease,
but this is still experimental. There has been some success with
using gene therapy to treat single gene disorders, such as primary
immune deficiency, but results are mixed.6 The National Institutes
of Health ("NIH") is funding a number of studies in gene therapy
research to develop treatments for cancer, heart disease, and AIDS.
This is an area of research that looks promising, but we have a long
way to go.
A fourth avenue for disease prevention is offering targeted
screening and interventions based on increased susceptibility. For
example, a person at risk for hereditary colorectal cancer may be
encouraged to be screened earlier or more frequently than is
normally recommended and may benefit from more intensive
screening methods, such as colonoscopy. Presymptomatic medical
therapies may also be helpful, whether they are as simple as taking
an aspirin a day or a prescribed medication.
These four main areas--drug therapy, environmental
modification, gene therapy, and targeted interventions-are the
key strategies we think of when we talk about using genetics and
genomics to help us treat and prevent disease.
Where are we today on the research continuum for preventing
common chronic diseases like heart disease, diabetes, and obesity?
The last estimate from the Human Genome Project ("HGP") was
that humans have between twenty and twenty-five thousand
genes, 8 as well as millions of variants of these genes. Common
chronic diseases result from the interactions of multiple genes with
multiple environmental
and behavioral factors.
Our
epidemiological and statistical methods are currently limited in
their ability to find meaningful associations among all of these
interacting factors.
Occasionally, chronic diseases may be due to the influence of
single genes. More often, smaller effects are reported in a way that
6. Rebecca H. Buckley, Primary Immunodeficiency Diseases: Dissectors
of the Immune System, 185 Immunol. Rev. 206, 206-19 (2002).
7. Muin J. Khoury et al., Do We Need Genomic Research for the
Prevention of Common Diseases with Environmental Causes?, 161 Am. J.
Epidemiol. 799, 799-805 (2005).
8. Human Genome Project, http://ww.oml.gov/sci/techresources/ Human_
Genome/home.shtml.
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can be misleading. For example, the popular press reported in late
2003 that doctors had found a link between MEF2A and heart
disease. 9 Some of the statements that appeared in print were along
the lines of: researchers identify defects in a gene that are directly
linked to heart attacks. Everyone who has this gene mutation is
destined to have the disease. If you do not have this gene, you
appear to be free from developing the disease. When findings are
presented this way, they can be misunderstood by the public.
If you look at the article itself, you will find that mutation of
the MEF2A is an inherited disorder with features of coronary
artery disease.' 0 This MEF2A mutation is very rare, occurring in
very few families. The study was done in Iowa, where researchers
found a fairly large extended family that carried this lethal
mutation and, yes, almost all family members who had this
mutation ended up with coronary artery disease."
Findings from this study may contribute to our understanding
of factors that cause heart disease in the wider population but the
public needs to understand that it is not as simple as finding the
"heart disease gene," the "cancer gene," or the "diabetes gene."
However, after this news appeared in the popular press, there were
probably people going into their physicians' offices asking to be
tested for the "coronary artery disease gene."
Another very interesting area in genomic research is the search
for genetic factors that play a role in the effectiveness of diet and
physical activity. Why, given the same body mass index, are some
people who engage in an exercise program successful while others
are not?
Certainly it is more than just determination and
metabolism!
I wanted to show the Obesity Gene Map Database
("OGMD") 12 because this comes from the Pennington Biomedical
Research Center and Dr. Bouchard is the senior author on these
papers. The OGMD is a wonderful example of an informatics tool
for genomics population health research, the challenge of which
extends well beyond genotyping and collecting the data.' 3 We are
deluged with information, and we need better tools to organize this
information and determine what is meaningful. The OGMD
presents information on the different obesity syndromes and
phenotypes identified thus far, along with lots of information about
9. Lejin Wang et al., Mutation of MEF2A in an Inherited Disorderwith
FeaturesofCoronaryArtery Disease,302 Science 1578, 1578-81 (2003).
10. Id.
11. Id.
12. Obesity Gene Map Database, http://obesitygene.pbrc.edu/.
13. Stephen Chanock & Sholom Wacholder, One Gene and One Outcome?
No Way, 8 Trends in Molecular Med. 266, 266-69 (2002).
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linkage studies, candidate genes, and mouse models. To date, it
looks like there are over 300 genes and markers that have been
identified and associated with obesity.
Data-mining tools 14 are another invaluable resource. There are
so many publications that it is becoming virtually impossible for
researchers working in most areas of genomics to sort through the
Data-mining
literature and figure out what is important.
techniques can be used to identify pertinent literature as well as
find gene-gene, gene-environment, and gene-disease associations
that may not have been explicitly noted before. When they work
well, these data-mining techniques pull the most relevant materials
to the forefront and flag what is most interesting.
So, apart from a few obesity syndromes, are there any clinical
applications for obesity based on what we have learned from
genomic research so far? We have learned that "fat stores are
regulated over long periods of time by complex systems that
involve input and feedback from fatty tissues the brain and
endocrine glands, like the pancreas and thyroid. ' We also know
that these systems cannot be studied in a static fashion. We cannot
just measure a person's BMI at one point in time, and then look at
their susceptibility genes. The research is much more complex.
appears to be
The most promising area currently
pharmacogenomics, developing new drug strategies to target
satiety and numerous metabolic pathways. In the meantime, it is
important to realize that genetic susceptibilities are not destiny.
We can make an impact on obesity by modifying behaviors and
environment. Of course, for the most part, this approach at the
population level has not been easy or particularly effective.
What about Type 2 diabetes? Again, there are single gene
defects, such as those resulting in MODY, or Maturity Onset
Diabetes of Youth, as well as syndromes like insulin resistance,
where we have learned quite a bit. Like obesity, diabetes is due to
complex interactions of multiple genes and environmental factors.
The candidate gene approach has been used for the most part to
find genes that regulate insulin signaling and secretion. Genomewide scans in high-risk families have searched for major
susceptibility loci and studies of specific ethnic groups with high
rates of diabetes, such as the Pima Indians, have generated more
insight than we have into many other chronic diseases. However,
14. Ying Liu et al., Text Mining Functional Keywords Associated with
Genes, 11 Medinfo 292, 292-96 (2004).
15. CDC Office of Genomics and Disease Prevention, Obesity and
Genetics: What We Know, What We Don 't Know and What It Means, Feb.
2002, http://www.cdc.gov/genomics/info/perspectives/files/obesknow.htm.
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it is still not clear why diabetes clusters in some specific racial and
ethnic groups-for example, Native American, Hispanic, and some
Scandinavian populations.' 6 Other factors that help to predict the
onset of diabetes include obesity, insulin
resistance,
7
hyperglycemia, dyslipidemia, and family history.'
Family history as a risk factor for common diseases is
receiving renewed interest. A review of about fifteen different
studies looking at family history as a risk factor for diabetes shows
a consistent, positive association, with relative risk ranging
between 1.5 and six.' 8 The variation is due to the types of relatives
that were included in the family history assessment, the number of
relatives affected, age at disease onset, and so forth. 19 Although
the studies were not entirely comparable, the evidence indicates
that family history is a very strong risk factor for diabetes. Family
history is a genomic tool that reflects shared genetic
susceptibilities, environment, and behaviors.
One of the groundbreaking studies in family history was done
by Roger Williams and his group in Utah, where they conducted a
family history assessment in the school system. 20 They worked
with the Education Department to include a family history module
in their health education programs in the schools, and they covered
nearly the entire state.
Students took home a family history
questionnaire and called their relatives and solicited all kinds of
health information. 22 The researchers calculated a family history
risk score for cardiovascular disease based on this information and
identified families at high risk.23 Seventy-two percent of early
coronary heart disease ("CHD") occurred in just fourteen percent

16. Jared Diamond, The Double Puzzle of Diabetes,423 Nature 599, 599602 (2003).
17. The Expert Comm. On the Diagnosis and Classification of Diabetes
Mellitus, Report of the Expert Committee on the Diagnosisand Classificationof
DiabetesMellitus, 26 Diabetes Care S5, S5-20 (2003).
18. Tabitha A. Harrison et al., Family History of Diabetes as a Potential
PublicHealth Tool, 24 Am. J. Prey. Med. 152, 153-55 (2003).
19. Maren T. Scheuner et al., Family History: A Comprehensive Genetic
Risk Assessment Method for the Chronic Conditions of Adulthood, 71 Am. J.
Med. Genetics 315, 315-24 (1997).
20.
Roger R. Williams et al., Usefulness of CardiovascularFamilyHistory
Datafor Population-BasedPreventive Medicine and Medical Research (The
Health Family Tree Study and the NHLBI Family Heart Study), 87 Am. J.
Cardiol. 129, 129-35 (2001).
21. Id. at 130.
22. Id.
23. Id. at 130-31.
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of the families, and eighty-six
percent of early stroke occurred in
4
eleven percent of families.
These and similar studies have been the impetus for a number
of initiatives around the country to promote the use of family
history as a genomic tool for disease prevention. You may ask,
"Why focus on family history? Doctors have been collecting
family histories forever."
They have, but it has not been
systematic and often the information is not carefully assessed or
used for prevention. Usually a form is filled out in the waiting
room and then filed in a medical record. How can we better utilize
this family history? Perhaps we can use it to assess risks for
common chronic diseases and to influence early screening, or to
educate people about prevention measures, such as behavior
changes.
At the CDC, we began an initiative in 2002 in collaboration
with several NIH institutes, a number of professional
organizations, and academic institutions to evaluate the use of
family history for assessing risk of common diseases and
influencing early detection and prevention strategies. We began
with a review of the literature to identify gaps in our knowledge of
family history as a risk factor for chronic diseases. We brought
together a group of experts to present the evidence at a workshop
in February 2003 and published a series of papers based on the
25
presentations in the American Journal of Preventive Medicine.
We then formed a work group and started examining the family
history tools and strategies that were currently in use. We came up
with some criteria for what we thought would make a good family
history tool for public health. Now we are in the process of
developing a new tool with a contractor and will conduct extensive
pilot testing and evaluation studies. If we find that this tool is valid
and useful, we will follow with public health campaigns about the
importance of knowing your family history and provide education
programs to improve the use of family history in clinical settings.
The tool will include a data collection component where
individuals can answer questions about the health history of their
close relatives, risk assessment algorithms that will provide a
qualitative assessment of risk for each disease included.in the tool,
and a report that will include suggested prevention strategies. For
24. Steven C. Hunt et al., Family History Assessment: Strategies for
Prevention of CardiovascularDisease, 24 Am. J. Prev. Med. 136, 137-38
(2003).
25. Paula W. Yoon et al., ResearchPrioritiesfor EvaluatingFamily History
in the Prevention of Common Chronic Diseases, 24 Am. J. Prey. Med. 128,
128-35 (2003).
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example, someone at moderate familial risk for heart disease who
smokes, is overweight, does not exercise, and eats high levels of
saturated fat might be given a priority list of behaviors to change
based on their family history. Individuals with a high familial risk
for colorectal cancer may need a genetic work-up, and earlier,
more frequent, and intensive screening.
The prototype of the tool focuses on six diseases: heart
disease, stroke, diabetes, colorectal cancer, breast cancer, and
Three research groups-the University of
ovarian cancer.
Michigan School of Medicine, Evanston Northwest Health Care
Research Institute, and Case Western Reserve University-will
conduct an evaluation of the tool when it is completed. The study
will determine if familial risk assessment and personalized
prevention recommendations are effective in motivating people to
change their lifestyle and screening behaviors.
In summary, specific measures must be taken to translate this
new science of genomics into tools and processes that are going to
help us treat and prevent disease. We need large-scale, populationbased collaborative research because, when you start looking at
multiple genes and multiple environmental factors to stratify risks,
you need big numbers to find meaningful associations. The new
biobanks now being created in some countries may help provide
the large population samples that will be needed. We also need to
develop complementary statistical methods because those we have
now are not sufficient to grasp the complexity of the data. We
need public health and clinical assessments of emerging genetic
technologies. We need to look seriously at the validity and utility
of what we are doing and the tools we are developing-including
genetic tests. Just because we can do something does not mean
that we should do it, especially on a population basis. And, we
need to thoroughly evaluate new genomic tools and tests in order
to develop evidenced-based policies and practices.
Returning to the translation continuum, there is a particular
need to focus on the validation gap. Studies must be done to
validate what is being undertaken, in terms of analytic validity,
clinical validity, clinical utility, and the ethical, legal, and social
issues that are associated with the technology. There are some
areas where this has been done fairly well-for example, in the
area of breast cancer testing. I think most people would agree that
BRCA1 and BRCA2 testing as presently done-in appropriate
groups of women, who are at very high risk and meet the criteria
for testing based on family history-has been shown to be valid
and useful.
Other tests have totally skipped the validation process and have
gone directly to the consumer, such as a cardiogenomic and
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nutrigenomic profiles offered by several companies. You send
your buccal sample by mail; they do a series of analyses on certain
genetic susceptibility genes and then give you a profile of your risk
of disease with some suggested preventive measures. The problem
with these tests is that the data showing validity and utility, if they
even exist, are not in the public domain. How can we develop
effective and safe policies and practice guidelines with no
information about their validity and utility? These are some of the
challenges that will face public health in the new genomic era.
The research is very exciting and there is much promise for
finding new strategies to prevent and treat disease, but we must
continue to emphasize the importance of validation and the
adoption of evidenced-based practices.

